Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
R-Pharm
Age
20–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women aged 20 years or older
Patients with metastatic breast cancer whose primary lesion was definitely diagnosed to be breast by histological or cellular examination
You may not be if
Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≥ 2
Clareo Health | Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
